0000950170-24-002240.txt : 20240104
0000950170-24-002240.hdr.sgml : 20240104
20240104195457
ACCESSION NUMBER: 0000950170-24-002240
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Durgam Suresh K.
CENTRAL INDEX KEY: 0001829958
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 24514102
MAIL ADDRESS:
STREET 1: C/O INTER-CELLULAR THERAPIES, INC.
STREET 2: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
ownership.xml
4
X0508
4
2024-01-02
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001829958
Durgam Suresh K.
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
false
true
false
false
EVP, Chief Medical Officer
true
Common Stock
2024-01-02
4
M
false
62282
19.87
A
62282
D
Common Stock
2024-01-02
4
S
false
37427
70.41
D
24855
D
Common Stock
2024-01-02
4
S
false
22645
70.80
D
2210
D
Common Stock
2024-01-02
4
S
false
2210
71.77
D
0
D
Stock Option (right to buy)
19.87
2024-01-02
4
M
false
62282
0
D
2028-08-15
Common Stock
62282
0
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.575 to $70.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.5764 to $71.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.5859 to $72.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
All shares underlying this option have vested.
/s/ Lawrence J. Hineline, Attorney-in-fact
2024-01-04